Lometrexol (DDATHF) 是一种抗嘌呤类抗叶酸 (antifolate) 药，可抑制甘氨酰胺核糖核苷酸甲酰基转移酶 (GARFT) 的活性，但不会引起可检测水平的 DNA 链断裂。Lometrexol 可以进一步抑制嘌呤从头合成，导致异常的细胞增殖，凋亡 (apoptosis) 和细胞周期停滞。Lometrexol 具有抗癌活性。Lometrexol 还是一种有效的人丝氨酸羟甲基转移酶 1/2 (hSHMT1/2) 抑制剂。
| 生物活性 | Lometrexol (DDATHF), an antipurineantifolate, can inhibit the activity ofglycinamide ribonucleotide formyltransferase (GARFT)but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation andapoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor[1][2][3]. |
体外研究
(In Vitro) | Lometrexol (DDATHF) binds tightly to GART, resulting in a rapid and prolonged depletion of intracellular purine ribonucleotides[3].
Lometrexol (1-30 μM; 2-10 hours) induces rapid and complete growth inhibition in L1210 cells[3].
Lometrexol (1 μM; 2-24 hours) induces cell cycle arrest in murine leukemia L1210 cells[3].
Cell Viability Assay[3] | Cell Line: | Mouse leukemia L1210 cells | | Concentration: | 1, 30 μM | | Incubation Time: | 2, 4, 6, 8, 10 hours | | Result: | Induced rapid and complete growth inhibition. |
Cell Cycle Analysis[3] | Cell Line: | L1210 cells | | Concentration: | 1 μM | | Incubation Time: | 2, 4, 8, 12, 24 hours | | Result: | Caused a rapid loss of the G2/M phase population of cells and an early S phase accumulation of cells by 8 hours. By 24 h, the S phase population appeared to be slowly shifting to higher DNA content, and hence, from mid-to-late S phase. |
|
体内研究
(In Vivo) | Lometrexol (DDATHF; i.p.; 15-60 mg/kg; on gestation day 7.5) induces neural tube defects (NTDs) by disturbing purine metabolism and increases the rate of embryonic resorption and growth retardation in a dose-dependent manner[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) decreases glycinamide ribonucleotide formyl transferase (GARFT) activity and Changes of ATP, GTP, dATP and dGTP levels[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) induces abnormal proliferation and apoptosis exist in neural tube defects (NTDs)[1].
| Animal Model: | C57BL/6 mice (7-8 week, 18-20 g)[1] | | Dosage: | 15, 30, 35, 40, 45 and 60 mg/kg | | Administration: | Intraperitoneal injection; on gestation day 7.5 | | Result: | Increased the rate of embryonic resorption and growth retardation in a dose-dependent manner. |
| Animal Model: | C57BL/6 mice (7-8 week, 18-20 g)[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; on gestation day 7.5, for 0, 6, 24, 48 and 96 hours | | Result: | Inhibited glycinamide ribonucleotide formyl transferase (GARFT) activity and GARFT activity was maximally inhibited after at 6 hours.
Decreased the levels of ATP, GTP, dATP, and dGTP of NTDs embryonic brain tissue significantly at 6 hours.
|
| Animal Model: | C57BL/6 mice (7-8 week, 18-20 g)[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; on gestation day 7.5, for 4 days | | Result: | Decreased the expression of proliferation-related genes (Pcna, Foxg1 and Ptch1) and increased the expression of apoptosis-related genes (Bax, Casp8 and Casp9) in NTD groups. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : ≥ 40 mg/mL(90.20 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 2.2550 mL | 11.2752 mL | 22.5505 mL | | 5 mM | 0.4510 mL | 2.2550 mL | 4.5101 mL | | 10 mM | 0.2255 mL | 1.1275 mL | 2.2550 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 |
m.cnreagent.com